Medication Description: Octreotide
Synonym: Sandostatin, Sandostatin, Somatostatinum.
Synthetic peptide (octapeptide), similar in structure and action to natural (endogenous) somatostatin, but differs much more stability and duration of action.
Octreotide with a subcutaneous injection is rapidly absorbed; the maximum plasma concentration is reached within 30 minutes; when administered intravenously, it is allocated in 2 phases with a half-life of 10 and 90 minutes.
Use octreotide (sandostatin) to reduce the concentration of growth hormone with acromegaly, including in cases of insufficient efficacy of dopamine agonists (see Bromocptin); to relieve symptoms associated with endocrine tumors of the gatro-entero-pancreatic system; for the prevention of complications after operations on the pancreatic gland; with profuse secretory diarrhea and reflex diarrhea associated with AIDS, dumping syndrome, aster pancreatitis.
Assign usually subcutaneously. When acromegaly is administered at 0.05-0.1 mg (50-100 μg) at intervals of 8 or 12 hours. The dose is determined on the basis of determining the concentration of growth hormone, clinical symptoms, and tolerability. Usually the optimal daily dose is 0.3 mg. The maximum dosage dose is 1.5 mg.
For endocrine tumors of the gatro-entero-pancreatic system, 0.05 mg (50 µg) is administered 1-2 times a day, with a gradual increase (if necessary) up to 3 times a day.
For diarrhea, 0.1-0.2 mg is administered 2-3 times a day for 5-7 days.
For refractory diarrhea associated with AIDS, 0.1-0.2 mg is administered 3 times a day (if necessary up to 0.3 mg or more 3 times a day).
To prevent complications after surgery on the pancreas, administer 0.1 mg 3 times a day for 7 days, starting 1 hour before surgery.
The daily dose should not usually exceed 0.75 mg (750 μg) for adults.
Children should be administered at the rate of 0.001-0.01 mg (1-10 μg) per 1 kg of body weight.
Subcutaneous injections of the drug are painful.
In some cases, resorted to intravenous administration.
Octreotide must be used under close medical supervision with laboratory tests.
Local side effects include pain, itching, burning at the injection site.
Anorexia, nausea, vomiting, abdominal pain, diarrhea, steatorrhea can occur.
Possible violations of glucose tolerance and liver function, the appearance of stones in the biliary tract (with prolonged use of the drug).
Sometimes somatotropin-producing pituitary tumors can grow.
During pregnancy and lactation, the use of sandostatin is possible only by absolute indications.
Form release: injection for ampoules containing 0.05; 0.1 or 0.5 mg (50; 100 or 500 μg) in 1 ml; reusable vials containing 1 mg (1000 μg) in 5 ml of solvent.
Storage: at a temperature of +2 to +8 C (up to 2 weeks at room temperature).